Log in to save to my catalogue

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute ly...

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute ly...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6778639

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Tyrosine kinase inhibitor (TKI) administration after allogeneic hematopoietic stem cell transplantation (HSCT) may carry a survival benefit in Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL). Therefore, we investigated whether TKI prophylaxis for negative‐minimal residual disease (MRD) after HSCT would improve patient outcom...

Alternative Titles

Full title

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6778639

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6778639

Other Identifiers

ISSN

1347-9032

E-ISSN

1349-7006

DOI

10.1111/cas.14167

How to access this item